Status:
RECRUITING
Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Eligibility:
All Genders
18-75 years
Brief Summary
The goal of this study is to calculate pharmacokinetic parameters and to evaluate the trough levels of posaconazole reached in patients with different stages of mucositis, due to chemotherapy and tota...
Eligibility Criteria
Inclusion
- Patients receiving allogeneic stem cell transplantation - Treated with prophylactic posaconazole: oral suspension (200mg three times daily) or tablet (300mg once daily) to prevent invasive fungal infections
Exclusion
- Gastroparesis
- Vomiting or diarrhea within 2 hours after intake of posaconazole
- Concomitant administration of potent inducers of the enzyme UGT1A4: carbamazepine,phenytoin, phenobarbital, rifabutin, rifampicin,...
- Age under 18 years
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT01420562
Start Date
September 1 2011
End Date
March 1 2025
Last Update
July 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Leuven
Leuven, Vlaams-Brabant, Belgium, 3000